The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model

PURPOSE: The prognosis for patients diagnosed with glioblastoma multiforme (GBM) remains dismal, with current treatment prolonging survival only modestly. As such, there remains a strong need for novel therapeutic strategies. The janus kinase (JAK)2/signal transducer and activator of transcription (...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Katharine Victoria, Cseh, Orsolya, Aman, Ahmed, Weiss, Samuel, Luchman, Hema Artee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734728/
https://www.ncbi.nlm.nih.gov/pubmed/29253028
http://dx.doi.org/10.1371/journal.pone.0189670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734728/
https://www.ncbi.nlm.nih.gov/pubmed/29253028
http://dx.doi.org/10.1371/journal.pone.0189670

Ejemplares similares